This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Jilin Zixin Pharmaceutical IndustrialLtd Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Jilin Zixin Pharmaceutical IndustrialLtd's earnings have been declining at an average annual rate of -66.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 50.2% per year.
Belangrijke informatie
-66.3%
Groei van de winst
-66.6%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 10.9% |
Inkomstengroei | -50.2% |
Rendement op eigen vermogen | -87.3% |
Nettomarge | -793.4% |
Volgende winstupdate | 23 Aug 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Jilin Zixin Pharmaceutical IndustrialLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
31 Mar 23 | 150 | -1,189 | 655 | 4 |
31 Dec 22 | 144 | -1,189 | 650 | 7 |
30 Sep 22 | 145 | -1,219 | 630 | 8 |
30 Jun 22 | 153 | -1,178 | 595 | 13 |
31 Mar 22 | 192 | -1,105 | 592 | 12 |
01 Jan 22 | 247 | -998 | 556 | 10 |
30 Sep 21 | 248 | -770 | 267 | 17 |
30 Jun 21 | 294 | -698 | 286 | 12 |
31 Mar 21 | 289 | -696 | 264 | 17 |
31 Dec 20 | 286 | -706 | 283 | 16 |
30 Sep 20 | 343 | -280 | 310 | 15 |
30 Jun 20 | 463 | -201 | 273 | 16 |
31 Mar 20 | 756 | -20 | 336 | 37 |
31 Dec 19 | 859 | 70 | 318 | 40 |
30 Sep 19 | 760 | -82 | 296 | 66 |
30 Jun 19 | 997 | -45 | 372 | 76 |
31 Mar 19 | 1,141 | 19 | 356 | 46 |
31 Dec 18 | 1,325 | 174 | 356 | 46 |
30 Sep 18 | 1,854 | 542 | 433 | 46 |
30 Jun 18 | 1,715 | 538 | 415 | 41 |
31 Mar 18 | 1,493 | 472 | 388 | 45 |
31 Dec 17 | 1,327 | 372 | 381 | 41 |
30 Sep 17 | 1,006 | 247 | 302 | 7 |
30 Jun 17 | 925 | 253 | 279 | 0 |
31 Mar 17 | 859 | 188 | 287 | 0 |
31 Dec 16 | 820 | 163 | 283 | 0 |
30 Sep 16 | 874 | 142 | 301 | 0 |
30 Jun 16 | 755 | 57 | 295 | 0 |
31 Mar 16 | 666 | 45 | 274 | 0 |
31 Dec 15 | 633 | 40 | 271 | 0 |
30 Sep 15 | 689 | 68 | 246 | 0 |
30 Jun 15 | 690 | 73 | 250 | 0 |
31 Mar 15 | 663 | 47 | 264 | 0 |
31 Dec 14 | 776 | 47 | 271 | 0 |
30 Sep 14 | 568 | -30 | 272 | 0 |
30 Jun 14 | 579 | 7 | 244 | 0 |
31 Mar 14 | 626 | 37 | 222 | 0 |
31 Dec 13 | 475 | 50 | 196 | 0 |
30 Sep 13 | 411 | 52 | 164 | 0 |
30 Jun 13 | 372 | 51 | 153 | 0 |
31 Mar 13 | 430 | 97 | 135 | 0 |
31 Dec 12 | 419 | 86 | 132 | 0 |
30 Sep 12 | 716 | 126 | 222 | 0 |
Kwaliteitswinsten: 002118 is currently unprofitable.
Groeiende winstmarge: 002118 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002118 is unprofitable, and losses have increased over the past 5 years at a rate of 66.3% per year.
Versnelling van de groei: Unable to compare 002118's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 002118 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.6%).
Rendement op eigen vermogen
Hoge ROE: 002118 has a negative Return on Equity (-87.33%), as it is currently unprofitable.